JP2024023228A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2024023228A5 JP2024023228A5 JP2023188623A JP2023188623A JP2024023228A5 JP 2024023228 A5 JP2024023228 A5 JP 2024023228A5 JP 2023188623 A JP2023188623 A JP 2023188623A JP 2023188623 A JP2023188623 A JP 2023188623A JP 2024023228 A5 JP2024023228 A5 JP 2024023228A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- cancer
- molecule
- hla
- antigen
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762506674P | 2017-05-16 | 2017-05-16 | |
| US62/506,674 | 2017-05-16 | ||
| PCT/US2018/032996 WO2018213467A1 (en) | 2017-05-16 | 2018-05-16 | Manabodies and methods of using |
| JP2019563546A JP7381345B2 (ja) | 2017-05-16 | 2018-05-16 | Ｍａｎａボディおよび使用方法 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019563546A Division JP7381345B2 (ja) | 2017-05-16 | 2018-05-16 | Ｍａｎａボディおよび使用方法 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2024023228A JP2024023228A (ja) | 2024-02-21 |
| JP2024023228A5 true JP2024023228A5 (enExample) | 2024-08-01 |
| JP7701079B2 JP7701079B2 (ja) | 2025-07-01 |
Family
ID=64274676
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019563546A Active JP7381345B2 (ja) | 2017-05-16 | 2018-05-16 | Ｍａｎａボディおよび使用方法 |
| JP2023188623A Active JP7701079B2 (ja) | 2017-05-16 | 2023-11-02 | Ｍａｎａボディおよび使用方法 |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019563546A Active JP7381345B2 (ja) | 2017-05-16 | 2018-05-16 | Ｍａｎａボディおよび使用方法 |
Country Status (7)
| Country | Link |
|---|---|
| US (2) | US11807662B2 (enExample) |
| EP (2) | EP4644427A2 (enExample) |
| JP (2) | JP7381345B2 (enExample) |
| CN (1) | CN111406068A (enExample) |
| AU (2) | AU2018269370B2 (enExample) |
| CA (1) | CA3063905A1 (enExample) |
| WO (1) | WO2018213467A1 (enExample) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2018213467A1 (en) | 2017-05-16 | 2018-11-22 | The Johns Hopkins University | Manabodies and methods of using |
| EP3683229A1 (en) * | 2019-01-21 | 2020-07-22 | Charité - Universitätsmedizin Berlin | Specific t cell receptors against epitopes of mutant myd88l265p protein for adoptive t cell therapy |
| EP3927727A1 (en) | 2019-02-20 | 2021-12-29 | Fred Hutchinson Cancer Research Center | Binding proteins specific for ras neoantigens and uses thereof |
| KR20230031981A (ko) | 2019-05-14 | 2023-03-07 | 프로벤션 바이오, 인코포레이티드 | 제1형 당뇨병을 예방하기 위한 방법 및 조성물 |
| IL266728B (en) * | 2019-05-19 | 2020-11-30 | Yeda Res & Dev | Identification of recurrent mutant neopeptides |
| WO2021098822A1 (zh) * | 2019-11-21 | 2021-05-27 | 江苏恒瑞医药股份有限公司 | 一种双特异性抗体 |
| WO2021127184A1 (en) * | 2019-12-17 | 2021-06-24 | The Johns Hopkins University | MANAbodies TARGETING TUMOR ANTIGENS AND METHODS OF USING |
| KR20230092863A (ko) | 2020-06-11 | 2023-06-26 | 프로벤션 바이오, 인코포레이티드 | 제1형 당뇨병을 예방하기 위한 방법 및 조성물 |
| CA3175784A1 (en) * | 2020-06-17 | 2021-12-23 | Kunwar Shailubhai | Compositions and methods for augmenting chimeric antigen receptor (car) t cell therapies |
| US20240002541A1 (en) * | 2020-12-01 | 2024-01-04 | The Johns Hopkins University | Methods and materials for treating t cell cancers |
| CN116574748B (zh) * | 2023-07-10 | 2023-09-12 | 昆明医科大学 | 一种用于靶向KRAS高频突变肿瘤的嵌合型nTCR-T构建方法 |
| WO2025106598A1 (en) * | 2023-11-13 | 2025-05-22 | Clasp Therapeutics, Inc. | Modified mana-tces targeting tumor antigens and engaging t cell receptors, and methods of using thereof |
Family Cites Families (39)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6750325B1 (en) | 1989-12-21 | 2004-06-15 | Celltech R&D Limited | CD3 specific recombinant antibody |
| US6630584B1 (en) | 2000-03-16 | 2003-10-07 | Ramot At Tel-Aviv University Ltd. | Single chain antibody against mutant p53 |
| AU2003216341A1 (en) | 2002-02-20 | 2003-09-09 | Dyax Corporation | Mhc-peptide complex binding ligands |
| JP3738308B2 (ja) | 2002-11-29 | 2006-01-25 | 篤 村口 | 抗原特異的リンパ球抗原受容体遺伝子のクローニング方法 |
| EP3037105B1 (en) | 2003-06-27 | 2021-03-17 | Amgen Fremont Inc. | Antibodies directed to the deletion mutants of epidermal growth factor receptor and uses thereof |
| WO2005099361A2 (en) * | 2003-07-10 | 2005-10-27 | Vaccinex, Inc. | MHC CLASS I - PEPTIDE-ANTIBODY CONJUGATES WITH MODIFIED β2-MICROGLOBULIN |
| CA2554195C (en) * | 2004-01-23 | 2011-02-22 | Green Peptide Co., Ltd. | Peptide originating in epidermal growth factor receptor (egfr) |
| CA2567814C (en) | 2004-05-27 | 2013-07-23 | Jon A. Weidanz | Antibodies as t cell receptor mimics, methods of production and uses thereof |
| WO2005118635A2 (en) | 2004-06-03 | 2005-12-15 | Novimmune S.A. | Anti-cd3 antibodies and methods of use thereof |
| JP2008533986A (ja) | 2005-03-25 | 2008-08-28 | ラモト アット テル アヴィヴ ユニヴァーシティ リミテッド | 変異型ｐ５３の共通エピトープに対するヒト合成単鎖抗体およびその使用 |
| CN101228187A (zh) | 2005-03-25 | 2008-07-23 | 特拉维夫大学拉莫特有限公司 | 针对突变p53的共同表位的人合成单链抗体及其用途 |
| WO2007033230A2 (en) | 2005-09-12 | 2007-03-22 | Novimmune S.A. | Anti-cd3 antibody formulations |
| KR20080090441A (ko) | 2005-12-21 | 2008-10-08 | 메디뮨 엘엘씨 | Ｅｐｈａ２ ｂｉｔｅ 분자 및 이의 용도 |
| SG10201602159VA (en) | 2011-02-11 | 2016-04-28 | Sloan Kettering Inst Cancer | Hla-restricted, peptide-specific antigen binding proteins |
| BR112013029893A2 (pt) | 2011-05-21 | 2017-05-30 | Macrogenics Inc | molécula de ligação a cd3, anticorpo de ligação a cd3, diacorpo de ligação a cd3 e composição farmacêutica |
| SI2794658T1 (sl) * | 2011-12-19 | 2017-05-31 | Synimmune Gmbh | Bispecifična molekula protitelesa |
| MX378463B (es) | 2013-02-26 | 2025-03-10 | Memorial Sloan Kettering Cancer Center | Composiciones y usos de las mismas para inmunoterapia. |
| ES2939760T3 (es) | 2014-03-15 | 2023-04-26 | Novartis Ag | Tratamiento de cáncer utilizando un receptor quimérico para antígenos |
| JP6673848B2 (ja) | 2014-04-03 | 2020-03-25 | セレクティスＣｅｌｌｅｃｔｉｓ | 癌免疫療法のためのｃｄ３３特異的キメラ抗原受容体 |
| US9611325B2 (en) | 2014-07-21 | 2017-04-04 | Wuhan Yzy Biopharma Co., Ltd. | Construction and application of bispecific antibody HER2xCD3 |
| SI3223850T1 (sl) | 2014-11-26 | 2020-09-30 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Anti-mutiran kras T-celični receptorji |
| WO2016154047A2 (en) | 2015-03-20 | 2016-09-29 | Memorial Sloan-Kettering Cancer Center | Monoclonal antigen-binding proteins to intracellular oncogene products |
| US20180086832A1 (en) | 2015-03-23 | 2018-03-29 | The Johns Hopkins University | Hla-restricted epitopes encoded by somatically mutated genes |
| WO2016166139A1 (en) * | 2015-04-14 | 2016-10-20 | Eberhard Karls Universität Tübingen | Bispecific fusion proteins for enhancing immune responses of lymphocytes against tumor cells |
| IL302102A (en) * | 2015-05-20 | 2023-06-01 | Dana Farber Cancer Inst Inc | shared neoantigens |
| NL2014935B1 (en) * | 2015-06-08 | 2017-02-03 | Applied Immune Tech Ltd | T cell receptor like antibodies having fine specificity. |
| IL281396B (en) | 2015-06-09 | 2022-07-01 | Memorial Sloan Kettering Cancer Center | T cell receptor-like antibody agents specific for ebv latent membrane protein 2a peptide presented by human hla |
| GB201513921D0 (en) | 2015-08-05 | 2015-09-23 | Immatics Biotechnologies Gmbh | Novel peptides and combination of peptides for use in immunotherapy against prostate cancer and other cancers |
| DK3350213T3 (da) | 2015-09-15 | 2021-06-21 | Us Health | T-cellereceptorer som genkender hla-cw8-begrænset muteret kras |
| LT3411404T (lt) | 2016-02-03 | 2022-12-27 | Amgen Research (Munich) Gmbh | Psma ir cd3 bispecifiniai, t ląsteles aktyvuojantys antikūno konstruktai |
| SG11201805770UA (en) | 2016-02-03 | 2018-08-30 | Amgen Res Munich Gmbh | BCMA and CD3 Bispecific T Cell Engaging Antibody Constructs |
| US11401332B2 (en) | 2016-08-23 | 2022-08-02 | The Regents Of The University Of California | Proteolytically cleavable chimeric polypeptides and methods of use thereof |
| US20190240257A1 (en) | 2016-10-13 | 2019-08-08 | The Johns Hopkins University | Compositions and methods for identifying functional anti-tumor t cell responses |
| US20200325244A1 (en) * | 2020-05-18 | 2020-10-15 | Abexxa Biologics, Inc. | Antibodies and methods of use thereof |
| WO2018213467A1 (en) | 2017-05-16 | 2018-11-22 | The Johns Hopkins University | Manabodies and methods of using |
| CA3080274A1 (en) | 2017-09-29 | 2019-04-04 | The United States Of America, As Represented By The Secretary, Department Of Health & Human Services | Methods of isolating t cells having antigenic specificity for a p53 cancer-specific mutation |
| CN119162251A (zh) * | 2017-12-04 | 2024-12-20 | 美国卫生和人力服务部 | 针对突变的ras的hla i类限制性t细胞受体 |
| WO2021127184A1 (en) | 2019-12-17 | 2021-06-24 | The Johns Hopkins University | MANAbodies TARGETING TUMOR ANTIGENS AND METHODS OF USING |
| CN111344015B (zh) | 2019-12-23 | 2022-09-30 | 深圳市人民医院 | 一种用于癌症治疗的光纳米疫苗及其制备方法和应用 |
-
2018
- 2018-05-16 WO PCT/US2018/032996 patent/WO2018213467A1/en not_active Ceased
- 2018-05-16 US US16/614,005 patent/US11807662B2/en active Active
- 2018-05-16 EP EP25190769.7A patent/EP4644427A2/en active Pending
- 2018-05-16 CA CA3063905A patent/CA3063905A1/en active Pending
- 2018-05-16 EP EP18802867.4A patent/EP3635000A4/en not_active Withdrawn
- 2018-05-16 JP JP2019563546A patent/JP7381345B2/ja active Active
- 2018-05-16 AU AU2018269370A patent/AU2018269370B2/en active Active
- 2018-05-16 CN CN201880047554.3A patent/CN111406068A/zh active Pending
-
2023
- 2023-09-25 US US18/473,695 patent/US20240294648A1/en active Pending
- 2023-11-02 JP JP2023188623A patent/JP7701079B2/ja active Active
-
2025
- 2025-05-21 AU AU2025203767A patent/AU2025203767A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2024023228A5 (enExample) | ||
| JP2025065142A5 (enExample) | ||
| JP7573441B2 (ja) | ガイダンス及びナビゲーションコントロール蛋白質並びにその生産及び使用方法 | |
| JP2023123502A5 (enExample) | ||
| JP2019525771A5 (enExample) | ||
| WO2021008610A1 (en) | Anti-dll3 chimeric antigen receptors and uses thereof | |
| RU2019126655A (ru) | Нуклеиновые кислоты, кодирующие химерные рецепторы, полипептидные химерные рецепторы, кодируемые ими, векторы экспрессии, содержащие их, выделенные клетки-хозяева, содержащие их, композиции, содержащие выделенные клетки-хозяева, а также способы получения выделенных клеток-хозяев in vitro, способы выбора нуклеиновых кислот, кодирующих химерные рецепторы, in vitro и способы проведения клеточной иммунотерапии у субъекта, имеющего опухоль | |
| JP2018538277A5 (enExample) | ||
| JP2015527070A5 (enExample) | ||
| JP2020512973A5 (enExample) | ||
| JP2019535262A5 (enExample) | ||
| JPWO2019157533A5 (enExample) | ||
| CN115066274A (zh) | 三价结合分子 | |
| IL274806B1 (en) | T-cells comprising anti-cd38 and anti-cd138 chimeric antigen receptors and uses thereof | |
| JPWO2021184673A5 (enExample) | ||
| JPWO2019191120A5 (enExample) | ||
| JPWO2020051493A5 (enExample) | ||
| JPWO2020104676A5 (enExample) | ||
| JPWO2021127184A5 (enExample) | ||
| JPWO2022133169A5 (enExample) | ||
| JPWO2020037066A5 (enExample) | ||
| WO2024037628A1 (zh) | 一种双特异性抗体及其应用 | |
| JPWO2022170280A5 (enExample) | ||
| JPWO2023044456A5 (enExample) | ||
| JPWO2021102055A5 (enExample) |